stock
Quoin Pharmaceuticals Ltd DRC
NASDAQ | QNRX
7.48
USD
+0.00
(+0.00%
)AT CLOSE (AS OF Aug 15, 2025)
$4.3M
MARKET CAP
0.0076
P/E Ratio
958.65
EPS
$38
52 Week High
$5
52 Week Low
LIFE SCIENCES
Sector
QNRX Chart
Recent Chart
Price Action
1D
Candles
Trade Smarter
Automate your trading workflow with powerful tools — built for serious traders.
QNRX Technicals
QNRX Earnings
Yearly Income Statement (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Gross Profit | -$100K |
| Total Revenue | $0 |
| Cost Of Revenue | $100K |
| Costof Goods And Services Sold | $100K |
| Operating Income | -$9.6M |
| Selling General And Administrative | $5.9M |
| Research And Development | $3.5M |
| Operating Expenses | $9.5M |
| Investment Income Net | - |
| Net Interest Income | $558K |
| Interest Income | $558K |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $100K |
| Income Before Tax | -$9B |
| Income Tax Expense | -$9B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$9M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$9M |
| Ebitda | -$8.9M |
| Net Income | -$9M |
Revenue & Profitability
Earnings Performance
QNRX Financials
yearly Balance Sheet (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Total Assets | $16M |
| Total Current Assets | $15M |
| Cash And Cash Equivalents At Carrying Value | $3.6M |
| Cash And Short Term Investments | $3.6M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $783K |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $483K |
| Intangible Assets Excluding Goodwill | $483K |
| Goodwill | $483M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $10M |
| Other Current Assets | $869K |
| Other Non Current Assets | - |
| Total Liabilities | $6.5M |
| Total Current Liabilities | $4.2M |
| Current Accounts Payable | $906K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $600K |
| Total Non Current Liabilities | $2.3M |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $2.9M |
| Other Current Liabilities | $2.6M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $9.2M |
| Treasury Stock | - |
| Retained Earnings | -$55M |
| Common Stock | - |
| Common Stock Shares Outstanding | $134K |
yearly Cash Flow (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$7.9M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $100K |
| Capital Expenditures | $0 |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$1.9M |
| Cashflow From Financing | $11M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$9M |
yearly Income Statement (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Gross Profit | -$100K |
| Total Revenue | $0 |
| Cost Of Revenue | $100K |
| Costof Goods And Services Sold | $100K |
| Operating Income | -$9.6M |
| Selling General And Administrative | $5.9M |
| Research And Development | $3.5M |
| Operating Expenses | $9.5M |
| Investment Income Net | - |
| Net Interest Income | $558K |
| Interest Income | $558K |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $100K |
| Income Before Tax | -$9B |
| Income Tax Expense | -$9B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$9M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$9M |
| Ebitda | -$8.9M |
| Net Income | -$9M |
QNRX News
QNRX Profile
Quoin Pharmaceuticals Ltd DRC Profile
Sector: LIFE SCIENCES
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
None
Discover more tools and features to empower your trading
Explore FeaturesMarket data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.